Well, a reasonable question...

Perhaps a better question may be is if it show activity, eoujd it change the treatment plan?

That leads to another question, based on your clinical data, have you and your medical team discussed a decision to treat and if so, a plan?

There is a statistically strong probability at that PSA the scan shows nothing.

There is the possibility your insurance balks at the idea it if they approve, they are not do inclined to approve bother one anytime soon!

Is your PSA increasing?

Have you discussed adjuvant therapy with your medical team?

Have you looked at the guidelines such as NCCN and AUA, if so, what do they say?

You have choices...

Do nothing, continue to monitor, have decision criteria in place as when to image.

Generally you want to do SRT at a PSA of .2 to .3.

Even then you face decisions:

SRT to the prostate bed only?

SRT to the prostate bed and include the whole pelvic lymph nodes?

The choice may relate to GS, GG, PSADT, PSAV, any other data such as Decipher, Genetic testing...

Do you add short term systemic therapy to those choices?

What's the outcome you are seeking, curative, control...?

What would I do were I you? Well, nothing right now. I might discuss doing monthly PSA testing with my medical team instead of quarterly or semi-annually so as not to miss that .2-.3 window of opportunity.

All other things being equal, insurance...I would imagine at .2, as others have said, 30% chance it shows activity.

I would discuss with my medical team the options when your clinical data says it's time.

Finally, there's this- https://ancan.us14.list-manage.com/track/click

Kevin